Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
Brinker
Allen
A
Division of Drug Risk Evaluation, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA. brinkera@cder.fda.gov
Nourjah
Parivash
P
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002074:Butanones / Q000627:therapeutic use*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D011307:Drug Prescriptions; D004363:Drug Utilization; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D010045:Outpatients; D000077431:Oxaprozin; D010818:Practice Patterns, Physicians'; D011422:Propionates / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D011422:Propionates; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D000068579:Celecoxib; D000077430:Nabumetone; D000077431:Oxaprozin